A recent study conducted by researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health, in collaboration with the Malawi-Liverpool Wellcome Trust Clinical Research Programme, reveals that a single dose of the typhoid conjugate vaccine, Typbar TCV®, offers long-lasting protection against typhoid fever in children aged 9 months to 12 years. Published in The Lancet, the phase 3 clinical trial involved over 28,000 healthy children in Malawi, with half receiving the TCV and the other half a control vaccine. Over a four-year follow-up period, the TCV demonstrated an efficacy of 78.3%, with consistent effectiveness across all age groups. The study concludes that the TCV is highly effective in preventing typhoid fever, with only a marginal decrease in efficacy over time.
Single dose typhoid conjugate vaccine provides lasting efficacy in children
Updated on May 3, 2024